reports
- Damien Conover
Trump’s Blueprint to Lower Drug Prices Offers Minor Changes; No Big ...
The Trump administration’s policy paper titled “The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs†offers proposals that don’t impact our moat ratings in the Big Pharma and Biotech industries, and the pricing power of branded drugs in the U.S. still looks strong. The blueprint’s near-term focus largely supports increasing generic drug competition, slightly strengthening Medicare drug price negotiations, improving drug price transparency, and providi...
- Damien Conover
Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big P...
Trump’s policy speech on lowering drug prices didn’t offer many specifics and focused mostly on reducing middleman profits and raising drug prices overseas. Based on the 2019 U.S. government budget proposal and the Council of Economic Advisors white paper on drug policy, we expect only modest negative headwinds to branded drug prices. We continue to view moats within Big Pharma/Biotech industries as intact, supported by strong pricing power for patent protected drugs. We view the branded dru...
- Damien Conover
Lilly's growth outlook is improving through cutting costs and launchin...
Eli Lilly posted strong first-quarter results, ahead of both our expectations and those of consensus, but we don’t expect a major shift in our fair value estimate based on the minor outperformance. We continue to see Lilly as undervalued, with the investment community not fully appreciating the company’s new product launches and the projected long-term margin improvements. Also, the company’s strong recent drug launches continue to support our wide moat rating for the firm. On the top line...
- Damien Conover
Buoyed by New Drugs and Expense Controls, Lilly Posts Strong 1Q Result...
Eli Lilly posted strong first-quarter results, ahead of both our expectations and those of consensus, but we don’t expect a major shift in our fair value estimate based on the minor outperformance. We continue to see Lilly as undervalued, with the investment community not fully appreciating the company’s new product launches and the projected long-term margin improvements. Also, the company’s strong recent drug launches continue to support our wide moat rating for the firm. On the top line...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.